Chikungunya Fever: Clinical Trials

88 trials for Chikungunya Fever, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

47 completed, 8 not yet recruiting, 7 unknown, 6 active not recruiting. 23 Not applicable, 15 Phase 3, 12 Phase 2, 10 Phase 1, 2 Early Phase 1.

By phase and status

PhaseTrialsStatus
Not applicable23Completed 12, Not yet recruiting 4, Terminated 3, Enrolling by invitation 1, Recruiting 1, Suspended 1, Unknown 1
Phase 315Completed 5, Active not recruiting 3, Recruiting 2, Terminated 2, Withdrawn 2, Not yet recruiting 1
Phase 212Completed 8, Not yet recruiting 1, Recruiting 1, Terminated 1, Unknown 1
Phase 110Completed 9, Unknown 1
Early Phase 12Not yet recruiting 1, Unknown 1
Phase 41Recruiting 1

Follow Chikungunya Fever: new trials by email Literature Review of Chikungunya Fever trials Research Report on Chikungunya Fever

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Against Chikungunya Virus and Neonatal Infection
plasma transfusion : PC-CHIK-V - Chikungunya Virus Infection, Neonatal
Not applicableRecruitingCentre Hospitalier Universitaire de la Réunion602027-08-012026-09-15
Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.
DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555) - Dengue, Chikungunya
Phase 3Not yet recruitingButantan Institute9002027-03-312026-07-16
Evaluation of IXCHIQ® Vaccine Immunogenicity
IXCHIQ vaccine - Healthy Adult, Healthy Adolescents
Phase 2Not yet recruitingMauro Martins Teixeira752026-09-242026-09-29
Smart Analysis and Decision-Making for Emerging Infectious Diseases
Multi-Agent Integrated Smart Toolkit for Emerging Infectious Diseases, Routine Practices - Emerging Infectious Diseases, COVID-19
Not applicableEnrolling by invitationPeking University1082026-08-102026-08-19
A Phase I Study of PepGNP-ChikV in Healthy Volunteers
PepGNP-ChikV, Placebo - Chikungunya, Chikungunya Fever
Early Phase 1Not yet recruitingGylden Pharma Ltd402026-08-032026-04-29
Effects Of A Rehabilitation Protocol On Muscle Strength, Muscle Fatigue And Postural Control In Post-Dengue And Chikungunya Patients
Exercise - Dengue, Chikungunya
Not applicableNot yet recruitingUniversidade do Estado do Pará542026-07-012026-05-26
VLA1553-403 Pregnancy Surveillance Study
Live-attenuated CHIKV vaccine VLA1553, Vaccine(s) approved for use during pregnancy by the MoH - Chikungunya Virus Infection
Enrolling by invitationValneva Austria GmbH2002026-06-112026-07-20
An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults
CHIKV VLP vaccine, Placebo - Chikungunya Virus
Phase 3RecruitingBavarian Nordic61442026-05-262026-06-29
A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.
BBV87 Chikungunya vaccine, Placebo - Active Immunisation for Chikungunya Virus Infection
Phase 2 / Phase 3RecruitingBharat Biotech International Limited10002026-04-202026-04-29
Using Digital Technology for the Prevention of Aedes-Borne Diseases in Colombian Communities
Full intervention, Partial intervention - Dengue, Zika
Not applicableCompletedUniversity of Freiburg9002026-03-262026-04-08
A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children
VLA1553, Control - Chikungunya Virus Infection
Phase 3WithdrawnValneva Austria GmbH2026-02-062025-12-31
Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
Live-attenuated CHIKV vaccine VLA1553 - Chikungunya Virus Infection
Active not recruitingValneva Austria GmbH50002026-02-022026-07-21
Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil
Live-attenuated CHIKV vaccine VLA1553 - Chikungunya Virus Infection
Enrolling by invitationValneva Austria GmbH12002026-02-022026-07-17
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
Dengue, Chikungunya
RecruitingInstitut Pasteur du Cambodge100002025-12-182026-01-22
Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
Live-attenuated CHIKV vaccine VLA1553 - Chikungunya Virus Infection
Active not recruitingValneva Austria GmbH53542025-09-222026-02-11
Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections
Exanthema, Dengue Fever
Not yet recruitingHospital Israelita Albert Einstein8302025-09-012025-08-08
A Clinical Study on the Efficacy and Safety of Reduning Injection in the Treatment of Chikungunya Fever
Reduning injection, The simulant of Reduning Injection - Chikungunya Fever
Not applicableNot yet recruitingJiangsu Kanion Pharmaceutical Co., Ltd4002025-08-282025-08-17
Xpert® Tropical Fever Test on GeneXpert® Edge X System
Xpert Tropical Fever test - Malaria Fever, Zika
Enrolling by invitationCepheid25002025-08-182026-04-09
The Interest of Systematic Screening for Dengue, Chikungunya, and Zika, in Malaria-negative Return Travelers
The retrospective analyses planned for these samples consist of serological analysis and molecular analysis (RT-PCR ) according to the date of symptoms ons - Arbovirus Infections
Active not recruitingUniversity Hospital, Strasbourg, France2002025-08-012025-08-08
Real-World Study on Chinese Medicine for Treating Chikungunya Fever
Chikungunya Fever
RecruitingGuangzhou University of Traditional Chinese Medicine6002025-07-262025-08-13

Showing 20 of 88. Sign in to see all of them.

Narrower conditions

Dengue (31)  ·  Zika Virus Infection (27)  ·  Arbovirus Infections (7)  ·  Malaria (7)  ·  Vector Borne Diseases (4)  ·  Communicable Diseases (3)  ·  Leishmaniasis (3)  ·  Leptospirosis (3)  ·  Measles (3)  ·  Brucellosis (2)  ·  COVID-19 (2)  ·  Disease (2)  ·  Encephalitis, Tick-Borne (2)  ·  Fever (2)

Broader conditions

Infections (88)  ·  RNA Virus Infections (88)  ·  Togaviridae Infections (88)  ·  Alphavirus Infections (87)  ·  Mosquito-Borne Diseases (86)  ·  Virus Diseases (86)  ·  Vector Borne Diseases (84)  ·  Arbovirus Infections (81)  ·  Flaviviridae Infections (34)  ·  Flavivirus Infections (34)  ·  Hemorrhagic Fevers, Viral (31)  ·  Pathological Conditions, Signs and Symptoms (12)  ·  Pathologic Processes (9)  ·  Parasitic Diseases (8)  ·  Protozoan Infections (8)

Interventions

Blood Specimen Collection (5)  ·  Exercise (2)  ·  Measles-Mumps-Rubella Vaccine (2)  ·  Seeds (2)  ·  Arthrocentesis (1)  ·  Chloroquine (1)  ·  Dosage Forms (1)  ·  Neuropsychological Tests (1)  ·  Observation (1)  ·  Phlebotomy (1)  ·  Resistance Training (1)  ·  Reverse Transcriptase Polymerase Chain Reaction (1)  ·  Saline Solution (1)  ·  Sodium Chloride (1)  ·  Transcranial Direct Current Stimulation (1)

Sponsors

Valneva Austria GmbH (11)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (8)  ·  Bavarian Nordic (7)  ·  Centre Hospitalier Universitaire de la Réunion (6)  ·  Themis Bioscience GmbH (4)  ·  Institut Pasteur (3)  ·  Bharat Biotech International Limited (2)  ·  Butantan Institute (2)  ·  Centre Hospitalier Universitaire de la Guadeloupe (2)  ·  University Hospital Center of Martinique (2)  ·  University of Heidelberg Medical Center (2)  ·  University of Notre Dame (2)  ·  University of Oxford (2)  ·  Agence Sanitaire et Sociale de Nouvelle Calédonie (1)  ·  Assistance Publique Hopitaux De Marseille (1)

Countries

United States (18)  ·  Brazil (14)  ·  France (10)  ·  Colombia (6)  ·  Mexico (5)  ·  Reunion (5)  ·  Germany (4)  ·  Guadeloupe (4)  ·  Puerto Rico (4)  ·  Cambodia (3)  ·  China (3)  ·  French Guiana (3)  ·  Dominican Republic (2)  ·  India (2)  ·  Martinique (2)

Top investigators

Myrielle Dupont-Rouzeyrol, PhD (3)  ·  Patrick Ajiboye, MD (3)  ·  Andre Cabie, MD (2)  ·  Clemente Diaz, MD (2)  ·  James McCarty, MD (2)  ·  Adi Utarini, MD, PhD (1)  ·  Adrian V Hill, DPhill FRCP (1)  ·  Aileen Y Chang, MD MSPH (1)  ·  Axel Kroeger, Prof. Dr. (1)  ·  Beatriz Parra, PhD (1)

Results publications

PMID 35709798, PMID 31878895, PMID 32497524, PMID 33422034, PMID 37254133, PMID 37321235, PMID 25132507, PMID 25739878, PMID 27694629, PMID 27705091, PMID 29266856, PMID 29855331, PMID 30409443, PMID 30572920, PMID 31672665, PMID 32163420, PMID 32220283, PMID 32286643, PMID 32450914, PMID 33686914, PMID 33828518, PMID 33836004, PMID 34107180, PMID 34330906, PMID 34454432, PMID 34529649, PMID 34582377, PMID 34718636, PMID 34887572, PMID 34900237, PMID 35210606, PMID 35236394, PMID 35255839, PMID 36384430, PMID 37068115, PMID 37690874, PMID 38032857, PMID 38294972, PMID 38794811, PMID 39004524, PMID 39067885, PMID 39116904, PMID 39146946, PMID 39243794, PMID 39255380, PMID 39297691, PMID 39543943, PMID 39954701, PMID 39998495, PMID 40158524

NIH funding

2014 (1), 2015 (1), 2018 (1), 2025 (1), U01AI148069 (1), U44AI152995 (1)